Patents Issued in June 18, 2024
-
Patent number: 12012597Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.Type: GrantFiled: September 15, 2022Date of Patent: June 18, 2024Assignee: ARIZ Precision Medicine, Inc.Inventors: Lonnie L. Bookbinder, Narendra K. Vaish, Brad J. Niles, Jonathan Flynn, Nicole Nunez
-
Patent number: 12012598Abstract: The present invention relates to an artificially manipulated immune system having an improved immune effect. More particularly, the present invention relates to an immune system having functions artificially altered which comprises artificially manipulated immunoregulatory elements and cells containing the same. Contemplated according to a particular embodiment is an immune system comprising artificially manipulated immunoregulatory genes such as PD-1, CTLA-4, A20, DGK?, DGK?, FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, and/or expression products thereof.Type: GrantFiled: August 14, 2017Date of Patent: June 18, 2024Assignee: TOOLGEN INCORPORATEDInventors: Seok Joong Kim, Yoon-Young Kim, Ho-Sung Yu, In-Young Jung, Jung Min Lee
-
Patent number: 12012599Abstract: This disclosure provides data showing that LEFTY inhibits differentiation-promoting pathways such as BMP7/pSMAD5 in breast cancer cell lines, over and above its known role of inhibiting Nodal/pSMAD2. LEFTY competes with BMP7 to bind to its cell surface receptor BMPR2, leading to inhibition of pSMAD5. The LEFTY-BMPR2 interaction is dominant over BMP-BMPR2 in tumorigenic cells, resulting in diminished pSMAD status, whereas in non-tumorigenic cells, there is minimal LEFTY-BMPR2 interaction, increased BMP7-BMPR2 association, and elevated pSMAD. Compositions and methods for inducing or inhibiting expression and/or the activity of LEFTY and BMP proteins are described, which can be used in diagnosis and therapy of cancer and other conditions, and to promote proliferation of stem cells.Type: GrantFiled: April 15, 2019Date of Patent: June 18, 2024Assignees: CZ Biohub SF, LLC, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael F. Clarke, Neethan A. Lobo, Maider Zabala Ugalde, Jane Antony
-
Patent number: 12012600Abstract: Provided are immunostimulatory bacteria and oncolytic viruses, and pharmaceutical compositions containing the bacteria and/or viruses, that act as three prime repair exonuclease 1 (TREX1) antagonists. The bacteria and viruses are for treating tumors that are human papillomavirus (HPV) positive or that have a high tumor mutational burden (TMB). The immunostimulatory bacteria and oncolytic viruses encode therapeutic products such RNAi, such as shRNA and microRNA, that mediate gene disruption and/or inhibit expression of TREX1, or that inhibit TREX1. The bacteria contain additional modifications to enhance their anti-tumor activity. The bacteria and viruses are used for treatment of tumors in which TREX1 expression correlates with the presence of the tumor or properties of the tumor, such that inhibition of TREX1 advantageously treats the tumor.Type: GrantFiled: December 22, 2021Date of Patent: June 18, 2024Assignee: Actym Therapeutics, Inc.Inventors: Christopher D. Thanos, Laura Hix Glickman
-
Patent number: 12012601Abstract: Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and/or Bcr-Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome.Type: GrantFiled: January 15, 2021Date of Patent: June 18, 2024Assignee: BIO-PATH HOLDINGS, INC.Inventor: Ana Tari Ashizawa
-
Patent number: 12012602Abstract: The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.Type: GrantFiled: March 9, 2018Date of Patent: June 18, 2024Assignee: The Medical College of Wisconsin, Inc.Inventors: Daniel M. Lipinski, Chris A. Reid
-
Patent number: 12012603Abstract: Herein we demonstrate that the mitochondrial genome influences temperature tolerance in Saccharomyces yeasts. The present invention provides methods for manipulating the mitotype of yeast, including methods to produce synthetic yeast hybrids with a selected mitotype and methods to exchange the native mitochondrial DNA (mtDNA) present in polyploid yeast with mtDNA from a desired source. Saccharomyces cerevisiae×Saccharomyces eubayanus hybrids with selected mitotypes are also provided. The yeast and methods of the present invention may be utilized in a variety of applications, including in fermentation to produce beer and wine.Type: GrantFiled: August 7, 2019Date of Patent: June 18, 2024Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Chris Todd Hittinger, David Peris Navarro, EmilyClare Patricia Baker
-
Patent number: 12012604Abstract: The present invention relates to a yeast cell that is genetically modified comprising: a) a disruption of one or more aldehyde dehydrogenase (E.C:1.2.1.4) native to the yeast; b) one or more nucleotide sequence encoding a heterologous NAD+-dependent acetylating acetaldehyde dehydrogenase (E.C. 1.2.1.10); c) one or more nucleotide sequence encoding a homologous or heterologous acetyl-CoA synthetase (E.C. 6.2.1.1); and d) a modification that leads to reduction of glycerol 3-phosphate phosphohydrolase (E.C. 3.1.3.21) and/or glycerol 3-phosphate dehydrogenase (E.C. 1.1.1.8 or E.C. 1.1.5.3) activity, native to the yeast.Type: GrantFiled: June 14, 2021Date of Patent: June 18, 2024Assignee: Danisco US Inc.Inventors: Paul Klaassen, Jozef Petrus Johannes Schmitz, Paulus Petrus De Waal, Arjen Bouma
-
Patent number: 12012605Abstract: Compositions and methods for obtaining plant cells with modified Ht1 nucleotide sequences, modified NLB18 sequences, or both, are provided herein. The methods involve introducing double-strand breaks into the maize genome in an endogenous Ht1 encoding sequence, an endogenous NLB18 encoding sequence, or both, to modify the genomic sequence in order to enhance northern leaf blight resistance of a plant produced from the plant cell. Further provided are methods that introduce resistant alleles of Ht1 and/or NLB18 into specific sites in the genome. Plants produced by the plant cells, and seeds produced from the plants are also included. Guide polynucleotides are also provided for the use of the CRISPR-Cas system in inducing double strand breaks.Type: GrantFiled: October 10, 2017Date of Patent: June 18, 2024Assignee: PIONEER HI-BRED INTERNATIONAL, INC.Inventors: Huirong Gao, Bailin Li, Robert B Meeley, Leandro Daniel Perugini, Girma M Tabor
-
Patent number: 12012606Abstract: Methods and systems for outputting data for transmission in a wireless local area network (WLAN) are disclosed. The method comprises generating a trigger frame for a first wireless communication device, the trigger frame comprising one or more subfields of bits at predefined bit locations within the trigger frame that are populated with values for a second wireless communication device to copy into a trigger based frame for transmission to the first wireless communication device.Type: GrantFiled: July 7, 2023Date of Patent: June 18, 2024Assignee: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Jung Hoon Suh, Yan Xin, Osama Aboul-Magd
-
Patent number: 12012607Abstract: Materials and methods are provided for making plants (e.g., Triticum varieties) with increased levels of dietary fiber, such as by making TALE nuclease-induced mutations in alleles encoding starch branching enzyme IIa (SBEIIa) and starch branching enzyme IIb (SBEIIb).Type: GrantFiled: May 2, 2019Date of Patent: June 18, 2024Assignee: CellectisInventors: Nicholas Baltes, Javier Gil Humanes
-
Patent number: 12012608Abstract: The present invention is directed to a transgenic maize plant or a part thereof comprising as transgene a nucleic acid capable of expressing a cell wall invertase or a functional part thereof, preferably a Chenopodium rubrum cell wall invertase or a functional part thereof, wherein as a result of the expression of the cell wall invertase or a functional part thereof the transgenic maize plant exhibits an enhanced tolerance to abiotic stress and/or an increased yield, to a method of producing such transgenic maize plant, to method of enhancing the tolerance to abiotic stress of a maize plant and/or of increasing yield potential of a maize plant, to a nucleic acid capable of expressing a cell wall invertase or a functional part thereof, preferably a Chenopodium rubrum cell wall invertase or a functional part thereof, to a vector comprising such nucleic acid, the use of the nucleic acid or vector for enhancing the tolerance to abiotic stress of a maize plant, for increasing yield potential of a maize plant and/oType: GrantFiled: October 17, 2022Date of Patent: June 18, 2024Assignee: KWS SAAT SE & Co. KGaAInventors: Karl Pioch, Wolfgang Koch, Stefan Meldau
-
Patent number: 12012609Abstract: Various embodiments disclosed relate to conductive graphene matrix-encapsulated cells. A matrix-encapsulated cell includes an encapsulating polymer matrix including a biopolymer and graphene. The matrix-encapsulated cell also includes one or more of the cells encapsulated within the encapsulating polymer, wherein the graphene directly contacts at least some of the cells. The matrix encapsulating the one or more cells is electrically conductive.Type: GrantFiled: May 9, 2023Date of Patent: June 18, 2024Assignee: Iowa State University Research Foundation, Inc.Inventors: Nicole Nastaran Hashemi, Reza Montazami, Marilyn Christine McNamara, Jasmin Okuzono
-
Patent number: 12012610Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver GO sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for re-combinase mediated exchange (RMCE).Type: GrantFiled: November 7, 2017Date of Patent: June 18, 2024Assignee: Genovie ABInventors: Reagan Micheal Jarvis, Ryan Edward Hill, Luke Benjamin Pase
-
Patent number: 12012611Abstract: A serum-free complete medium for inducing differentiation of a mesenchymal stem cell to a corneal epithelial cell in the field of differentiation induction of stem cells, prepared by the following method: uniformly mixing the serum-free complete medium, containing 5-10 ?mol of resveratrol, 2-4 ?mol of icariin, 1-3 nmol of aspirin, 1-3 nmol of parathyroid hormone, 5-10 nmol of hydrocortisone, 1-3 mg of rapamycin, 2-10 ?g of testosterone, 2-10 ?g of EPO, 2-10 ?g of LIF and the balance of a corneal epithelial cell serum-free medium in per 1 L; and then performing sterilization by filtration.Type: GrantFiled: May 25, 2020Date of Patent: June 18, 2024Assignee: QINGDAO RESTORE BIOTECHNOLOGY CO., LTD.Inventors: Bingqiang Zhang, Mengmeng Chen, Wei Zou, Xueqi Fu
-
Patent number: 12012612Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors. The signals of the activating and blocking receptors can be modulated via the identity of a hinge.Type: GrantFiled: September 21, 2021Date of Patent: June 18, 2024Assignee: A2 BIOTHERAPEUTICS, INC.Inventor: Alexander Kamb
-
Patent number: 12012613Abstract: The present invention relates to a genetically modified hematopoietic stem cell comprising, in at least one globin gene comprised in the genome thereof, at least one transgene encoding a therapeutic protein or a therapeutic ribonucleic acid, the said transgene being placed under the control of the endogenous promoter of the said globin gene.Type: GrantFiled: January 11, 2019Date of Patent: June 18, 2024Assignees: Genethon, Institut National De La Sante Et De La Recherche MedicaleInventors: Mario Amendola, Giulia Pavani
-
Patent number: 12012614Abstract: The present invention belongs to the field of biomedicine, and relates to an inducer for inducing a mesenchymal stem cell to differentiate into an islet cell. An inducer for inducing a mesenchymal stem cell to differentiate into an islet cell consisted of the following components: GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO and VEGF. Each component in a inducer for inducing a mesenchymal stem cell to differentiate into an islet cell of the present invention is safe and non-toxic, requiring fewer steps and short time to induce differentiation, with high induction efficiency.Type: GrantFiled: May 25, 2020Date of Patent: June 18, 2024Assignee: QINGDAO RESTORE BIOTECHNOLOGY CO., LTD.Inventors: Bingqiang Zhang, Mengmeng Chen, Cuicui Li, Erpu Wang, Fubin Wang, Wei Zou, Xueqi Fu, Cuijuan Liu
-
Patent number: 12012615Abstract: The invention provides an in vitro method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells. The method comprises contacting an isolated somatic cell being reprogrammed into an iPS cell with an inhibitor of p53 function. The invention also provides an in vitro method of producing iPS cells. The method comprises bringing (a) nuclear reprogramming substances or nucleic acids encoding the nuclear reprogramming substances and (b) an inhibitor of p53 function into contact with a somatic cell.Type: GrantFiled: November 19, 2018Date of Patent: June 18, 2024Assignee: Kyoto UniversityInventors: Shinya Yamanaka, Kazutoshi Takahashi, Keisuke Okita
-
Patent number: 12012616Abstract: The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.Type: GrantFiled: November 30, 2018Date of Patent: June 18, 2024Assignee: Public University Corporation Yokohama City UniversityInventors: Hideki Taniguchi, Takanori Takebe, Keisuke Sekine
-
Patent number: 12012617Abstract: Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel.Type: GrantFiled: November 23, 2021Date of Patent: June 18, 2024Assignee: San Diego State University (SDSU) FoundationInventors: Forest Rohwer, Jeremy J. Barr
-
Patent number: 12012618Abstract: The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.Type: GrantFiled: September 9, 2022Date of Patent: June 18, 2024Assignee: Codexis, Inc.Inventors: Christopher Michael Micklitsch, Oscar Alvizo, Jovana Nazor, Harvinder Chagger Maniar, Mikayla Jianghongxia Krawczyk, Margie Tabuga Borra-Garske, Nandhitha Subramanian, Anna Fryszkowska, Nicholas M. Marshall, Agustina Rodriguez-Granillo, Deeptak Verma, Dewan Andrews
-
Patent number: 12012619Abstract: An NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. The enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.Type: GrantFiled: November 11, 2022Date of Patent: June 18, 2024Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITYInventors: Geun Joong Kim, Hun-Dong Lee, Su-Kyoung Yoo, Dae Eun Cheong, Chul-Ho Yun, Hye-Ji Choi, Sang-Oh Ahn
-
Patent number: 12012620Abstract: The present invention provides engineered peroxidase enzymes, polypeptides having peroxidase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing peroxidase enzymes are also provided. The present invention further provides compositions comprising the peroxidase enzymes and methods of using the engineered peroxidase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.Type: GrantFiled: September 3, 2020Date of Patent: June 18, 2024Assignee: Codexis, Inc.Inventors: Da Duan, Auric Anthony Sowell-Kantz, Aksiniya Lyubenova Petkova, Jovana Nazor, Nandhitha Subramanian, Oscar Alvizo
-
Patent number: 12012621Abstract: This disclosure provides systems, methods, and compositions for RNA-guided RNA-targeting CRISPR effectors for the treatment of diseases as well as diagnostics. In some embodiments, nucleotide deaminase functionalized CRISPR systems for RNA editing RNA knockdown, viral resistance, splicing modulation, RNA tracking, translation modulation, and epi-transcriptomic modifications are disclosed.Type: GrantFiled: July 1, 2021Date of Patent: June 18, 2024Assignee: Massachusetts Institute of TechnologyInventors: Omar Abudayyeh, Jonathan Gootenberg
-
Patent number: 12012622Abstract: [Problem] To provide: a novel enzyme which is derived from a microorganism other than Bacillus circulans and is highly selective for galactotrisaccharide production and with which the galactooligosaccharide can be highly efficiently produced; and a novel method capable of producing the galactooligosaccharide. [Solution] A method for producing a galatooligosaccharide, the method including bringing an enzyme having an amino acid sequence selected from the group consisting of (a) to (f) and cells of a bacterium belonging to the genus Paenibacillus and/or a galactooligosaccharide-producing enzyme for the bacterium, into contact with lactose. (a) An amino acid sequence of sequence number 1. (b) An amino acid sequence of sequence number 2. (c) An amino acid sequence of an enzyme having galactooligosaccharide-producing activity, the amino acid sequence being the amino acid sequence of sequence number 1 in which one to ten amino acids have been replaced, removed, or inserted.Type: GrantFiled: March 28, 2019Date of Patent: June 18, 2024Assignee: GODO SHUSEI CO., LTD.Inventors: Rei Odaka, Yasuhiro Baba, Junki Ogasawara, Jun Yoshikawa
-
Patent number: 12012623Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: GrantFiled: July 16, 2021Date of Patent: June 18, 2024Assignee: Novozymes A/SInventors: Svend Kaasgaard, Jens Oebro, Signe Eskildsen Larsen, Allan Svendsen, Annette Helle Johansen, Michael Skjoet, Carsten Andersen, Lars Beier, Esben Peter Friis, Miguel Duarte Guilherme Pereira Toscano, Mads Bjoernvad, Frank Winther Rasmussen, Liv Spaanger Christiansen
-
Patent number: 12012624Abstract: A genetically modified Bacillus subtilis strain has been transformed with an optimized vector, mainly for producing a D-psicose 3-epimerase.Type: GrantFiled: November 6, 2018Date of Patent: June 18, 2024Assignee: ROQUETTE FRERESInventors: Sébastien Maubourguet, Sophie Huchette, Claudia Borgmeier, Guido Meurer
-
Patent number: 12012625Abstract: A method for the preparation of bioactive compound by culturing a Bacillus species containing 16S rRNA having nucleotide sequence that is at least 80% identical to the nucleic acid sequence of the 16S rRNA of B. endophyticus DS43 of SEQ ID NO: 1. Tryptone soya broth (TSB) is an effective growth medium for the production of the bioactive compound. A growth medium used in the method contains date syrup and/or molasses. The isolated fluorescent bioactive compound has biocidal activity against bacteria including Serratia marcescens, Staphylococcus aureus, and Escherichia coli.Type: GrantFiled: November 18, 2020Date of Patent: June 18, 2024Assignee: Imam Abdulrahman Bin Faisal UniversityInventor: Mahmoud Mohamed Berekaa
-
Patent number: 12012626Abstract: In various aspects and embodiments, the invention provides microbial cells and methods for producing advanced glycosylation products from lower glycosylated intermediates. The microbial cell expresses one or more UDP-dependent glycosyl transferase enzymes in the cytoplasm, for glycosylation of the intermediates. When incubating the microbial strain with a plant extract or fraction thereof comprising the intermediates, these glycosylated intermediates are available for further glycosylation by the cell, and the advanced glycosylation products can be recovered from the media and/or microbial cells.Type: GrantFiled: December 9, 2021Date of Patent: June 18, 2024Assignee: Manus Bio Inc.Inventors: Ajikumar Parayil Kumaran, Christine Nicole S. Santos, Jason Eric Donald, Mary Elizabeth Fowler, Ryan N. Philippe, Christopher Scott Frei, Aaron Love
-
Patent number: 12012627Abstract: The present invention relates to the technical field of microbial fermentation engineering, and specifically to a method for producing psicose 3-epimerase by high-density fermentation. In view of the low expression level of psicose 3-epimerase and other problems existing in the current fermentation, by controlling the feeding rate in the fermentation process, improving the culture temperature in the middle and late stages of fermentation and other measures in the present invention, the OD value during the fermentation with recombinant Bacillus subtilis and the total enzyme activity of psicose 3-epimerase in the fermentation broth are significantly increased, the expression of psicose 3-epimerase is markedly improved, and the production cost of allulose is reduced. Therefore, the present invention has a very broad prospect of application in industry.Type: GrantFiled: January 15, 2023Date of Patent: June 18, 2024Assignee: HENAN ZHONGDA HENGYUAN BIOTECHNOLOGY STOCK CO., LTD.Inventors: Sanying Wang, Linzheng Li, Ziheng Jin, Yanjun Wen
-
Patent number: 12012628Abstract: The disclosure discloses a method to elevate the amount of steviol glycosides remained in the recrystallization mother liquor of Stevia extract, and belongs to the field of modification and extraction of natural compounds. The disclosure adopts lactase for highly specific catalytic hydrolysis of stevioside to convert stevioside into rubusoside which usually can only be obtained from leaves of Rubus suavissimus S. Lee; and meanwhile, after stevioside in the mother liquor glycosides is converted, since the polarity difference between rubusoside and rebaudioside A is far larger than the polarity difference between stevioside and rebaudioside A, rebaudioside A is more easily separated out of the mother liquor glycosides. A technology provided by the disclosure is also applicable to value increment of mixed steviol glycosides containing stevioside and is beneficial for separating out rebaudioside A from the mixed steviol glycosides.Type: GrantFiled: November 27, 2020Date of Patent: June 18, 2024Assignee: JIANGNAN UNIVERSITYInventors: Yongmei Xia, Zhuoyu Zhou, Ye Fan, Xueyi Hu, Yun Fang, Xiang Liu, Haijun Wang, Jing Wu, Fei Xu
-
Patent number: 12012629Abstract: The present invention is directed to the development of continuous processing technology for the purification of biopharmaceuticals and biological products, such as monoclonal antibodies, protein therapeutics, and vaccines. Methods for continuous processing of a biological product in a feed stream toward formulation of a purified bulk product are described.Type: GrantFiled: September 24, 2020Date of Patent: June 18, 2024Assignee: Sartorius Stedim Chromatography Systems Ltd.Inventors: Thomas C. Ransohoff, Marc A. T. Bisschops
-
Patent number: 12012630Abstract: A method for quantitatively determining the amount of acetaminophen in a sample with greater precision, greater sensitivity and fewer interactions and fewer spectral and chemical interferences with other compounds contained in the sample. The method includes acetaminophen being hydrolyzed and the resulting p-aminophenol being reacted with a compound of general formula (III): in the presence of an oxidant to form a compound of general formula (IV): wherein R1 and R2, independently of one another, are selected from H, —CH3, and —OCH3, R3 is —C2H5 and R4 is a C1-4 alkyl moiety with a terminal sulfonate group, with the proviso that at least one of R1 and R2 is —OCH3 and/or R4 additionally has at least one OH substituent, and then the amount of the compound of general formula (IV) in the reaction mixture being photometrically determined.Type: GrantFiled: January 8, 2019Date of Patent: June 18, 2024Assignee: DiaSys Diagnostic Systems GmbHInventors: Matthias Grimmler, Detlef Thônges, Pia Schu, Carolin Menzenbach, Laura Kreckel
-
Patent number: 12012631Abstract: The present disclosure provides improved methods for isolating asymmetrically-primed and/or asymmetrically-tagged nucleic acid complexes that find use in downstream analytical analyses, including sequence analysis. Compositions comprising such complexes and kits and systems for generating such complexes are also provided.Type: GrantFiled: January 15, 2021Date of Patent: June 18, 2024Assignee: Pacific Biosciences of California, Inc.Inventors: Lei Sun, Sassan Sheikholeslami, Natasha Popovich, David Christopher Scherer
-
Patent number: 12012632Abstract: A method for sequencing a biological molecule, such as a nucleic acid molecule, and a method for detecting and/or correcting sequencing error(s) in the sequencing results are provided. Kits and systems based on the above methods are also provided.Type: GrantFiled: August 7, 2020Date of Patent: June 18, 2024Assignee: CYGNUS BIOSCIENCES (BEIJING) CO., LTDInventors: Yanyi Huang, Zitian Chen, Wenxiong Zhou, Haifeng Duan, Li Kang, Shuo Qiao
-
Patent number: 12012633Abstract: Embodiments disclosed herein provide methods of using somatic mutations in mitochondrial genomes to retrospectively infer cell lineages in native contexts and to serve as genetic barcodes to measure clonal dynamics in complex cellular populations. Further, somatic mutations in mitochondrial DNA (mtDNA) are tracked by single cell genomic approaches for simultaneous analysis of single cell lineage and state. Applicants further show that mitochondrial mutations can be readily detected with contemporary single cell transcriptomic and epigenomic technologies to concomitantly capture gene expression profiles and chromatin accessibility, respectively.Type: GrantFiled: June 11, 2019Date of Patent: June 18, 2024Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Children's Medical Center Corporation, President and Fellows of Harvard CollegeInventors: Leif S. Ludwig, Caleb A. Lareau, Jacob C. Ulirsch, Aviv Regev, Vijay G. Sankaran, Jason Buenrostro, Christoph Muus
-
Patent number: 12012634Abstract: This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease.Type: GrantFiled: April 12, 2021Date of Patent: June 18, 2024Assignee: POPULATION BIO, INC.Inventors: Eli Hatchwell, Peggy S. Eis
-
Patent number: 12012635Abstract: The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.Type: GrantFiled: February 4, 2022Date of Patent: June 18, 2024Assignee: EWinger, Inc.Inventors: Edward E. Winger, Jane Reed
-
Patent number: 12012636Abstract: Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.Type: GrantFiled: February 17, 2022Date of Patent: June 18, 2024Assignee: Novartis AGInventors: Marianna Rowlands, Clemence Anne Jeanne Marie Tessier, Paul Andrew Whittaker
-
Patent number: 12012637Abstract: The present disclosure relates to methods for detecting and treating propranolol sensitive tumors.Type: GrantFiled: October 28, 2021Date of Patent: June 18, 2024Assignee: University of South FloridaInventor: Hana Totary-Jain
-
Patent number: 12012638Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample of a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: November 18, 2022Date of Patent: June 18, 2024Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Hiroko Sudo, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 12012639Abstract: Processes for isolating xylose from an aqueous solution. A representative process can comprise providing an aqueous solution comprising xylose; combining a boron compound with the aqueous solution to form a boron derivative of the xylose; isolating the boron derivative of the xylose from the aqueous solution as a precipitate; dissolving the boron derivative of the xylose in a solvent; and isolating the xylose from the solvent as a precipitate using a boron capture agent.Type: GrantFiled: December 11, 2018Date of Patent: June 18, 2024Assignee: University of Louisville Research Foundation, Inc.Inventors: Christopher T. Burns, Jagannadh Satyavolu, Michael H. Nantz
-
Patent number: 12012640Abstract: A method of forming a hot stamped coated steel product includes providing a precoated steel strip, the precoated steel strip including a base steel having a first side and a second side, and a precoating on at least one of the first side and the second side, the precoating being made of aluminum or an aluminum alloy; heating the precoated steel strip in a furnace, wherein the precoated strip experiences a temperature rise at a heating rate (Vc) between 4° and 12° C./s, wherein Vc is a mean heating rate between 20 and 700 C; removing the heated precoated steel strip from the furnace; and then hot stamping the precoated strip to deform the precoated steel strip into a hot stamped coated steel product, the hot stamped coated steel product having a coating including, proceeding from the base steel outwards: (a) an interdiffusion layer, (b) an intermediate layer, (c) an intermetallic layer, and (d) a superficial layer.Type: GrantFiled: December 12, 2023Date of Patent: June 18, 2024Assignee: ArcelorMittalInventors: Pascal Drillet, Dominique Spehner, Ronald Kefferstein
-
Patent number: 12012641Abstract: A method of forming a component includes providing a work-piece blank from a formable material. The method also includes engaging the work-piece blank with a transfer device. The method additionally includes austenitizing the work-piece blank in the transfer device via heating the blank to achieve austenite microstructure therein. The method also includes transferring the austenitized blank to a forming press using the transfer device. The method additionally includes forming the component via the forming press from the austenitized blank and quenching the formed component. A work-piece blank transfer system includes a transfer device having clamping arm(s) for engaging, holding, transferring, and releasing the work-piece blank. The transfer device also includes a heating element configured to austenitize the work-piece blank via heating the blank to achieve austenite microstructure therein.Type: GrantFiled: November 23, 2020Date of Patent: June 18, 2024Assignee: GM Global Technology Operations LLCInventors: Shane M. Anderson, Charles Enloe, Qi Lu, Jason J. Coryell, Adam D. Hodges
-
Patent number: 12012642Abstract: A method of selectively recovering palladium from a palladium-containing material comprises providing a leaching solution comprising hydrochloric acid, hydrogen peroxide, and an iron salt comprising one or both of ferric chloride or ferrous chloride and contacting a palladium-containing material with the leaching solution to dissolve palladium from the palladium-containing material. Related methods of selectively recovering palladium from a palladium-containing material are also disclosed.Type: GrantFiled: August 15, 2019Date of Patent: June 18, 2024Inventors: Tedd E. Lister, Luis A. Diaz Aldana
-
Patent number: 12012643Abstract: The present invention relates to a method for the recovery of palladium from an aqueous solution, comprising the steps of: (A) providing a dispersion comprising an aqueous dispersing phase comprising palladium(II), at least one non-ionic surfactant and at least one compound bearing a beta-dithiocarbonyl group, so as to form a hydrophobic complex of palladium(II) with the compound bearing a beta-dithiocarbonyl group; (B) heating the dispersion resulting from step (A) to a temperature at least equal to its cloud point so as to obtain the phase separation between the aqueous dispersing phase and a dispersed phase rich in surfactant comprising at least a part of said hydrophobic complex; (C) separating the dispersed phase rich in surfactant from the aqueous dispersing phase resulting from step (B); and (D) recovering the hydrophobic complex of palladium(II) with the compound bearing a beta-dithiocarbonyl group.Type: GrantFiled: October 2, 2019Date of Patent: June 18, 2024Assignee: UNIVERSITA' DEGLI STUDI DI CAGLIARInventors: Angela Serpe, Eros Perra, Americo Rigoldi
-
Patent number: 12012644Abstract: Acquisition of critical minerals via refinement from aqueous sources. Technological and geopolitical advantages—inure to conflict-free refinement of rare materials including critical minerals used in production of energy storage devices, among other applications. Additionally, the applied “clean tech” methods advance environmental goals such as those given in the Paris Agreement. Various site-specific system configurations and corresponding site-specific methods of operation bring to bear a panoply of economically viable approaches to critical mineral refinement. In some approaches, electrical power needed to drive refinement is provided by selected site-specific renewable energy sources. Real-world implementations involve co-locating a dissociative reactor with a geothermal energy plant near a salar or other source (preferably aqueous) of critical minerals therein. Refined critical minerals are produced on site.Type: GrantFiled: September 7, 2023Date of Patent: June 18, 2024Assignee: LYTEN, INC.Inventors: Michael Stowell, Bruce Gittleman
-
System and process for the recovery of titanium, titanium alloy, zirconium and zirconium alloy scrap
Patent number: 12012645Abstract: A system for the recovery of titanium, titanium alloys, zirconium and zirconium alloys is disclosed. The system is fed with a mixture of chips including titanium chips, titanium alloy chips, zirconium chips and zirconium alloy chips, ferromagnetic chips and electrically conductive non-ferromagnetic chips. The system has at least one magnetic separator, a drying device and an Eddy current separator.Type: GrantFiled: November 5, 2019Date of Patent: June 18, 2024Inventor: Gianluca Galeazzi -
Patent number: 12012646Abstract: Some variations provide an additively manufactured metal-containing component comprising (i) nickel, (ii) aluminum and/or titanium, and (iii) nanoparticles, wherein the sum of aluminum weight percentage and one-half of titanium weight percentage is at least 3 on a nanoparticle-free basis, and wherein the additively manufactured metal-containing component has a microstructure that is substantially crack-free with equiaxed grains. A feedstock composition is also provided, comprising metal-containing microparticles and nanoparticles, wherein the nanoparticles are chemically and/or physically disposed on surfaces of the microparticles, wherein the microparticles comprise (i) nickel and (ii) aluminum and/or titanium, and wherein the sum of aluminum weight percentage and one-half of titanium weight percentage is at least 3 on a nanoparticle-free basis.Type: GrantFiled: December 4, 2018Date of Patent: June 18, 2024Assignee: HRL Laboratories, LLCInventors: John H. Martin, Julie Miller, Brennan D. Yahata, Randall C. Schubert, Jacob M. Hundley